PR Newswire Asia's news > Biotechnology

 < Previous page   |   Title only   |   Print    Next page > 
     
Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA
SHANGHAI, HANGZHOU, China and BOSTON , April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on ...
2026-04-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
FDA Accepts NDA for TLX101-Px (Pixclara®)
MELBOURNE, Australia and INDIANAPOLIS , April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the United States (U.S.) Food and ...
2026-04-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
GenScript and Mimulus Partner to Industrialize DNA-Based Data Storage for the AI Era
The multi-year collaboration aims to scale molecular data storage infrastructure and unlock breakthrough cost efficiencies by 2030. ...
2026-04-09T    Banking/Financial Service   Biotechnology   Computer/Electronics   Health Care/Hospital 
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
SHANGHAI , April 9, 2026 /PRNewswire/ -- DualityBio ("DualityBio" or the "Company", Stock Code: 9606.HK) today announced that the Biologics License Application (BLA) for the investigational ...
2026-04-09T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease
ROCKVILLE, Md. , April 9, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant's dosing following the clearance of the Investigational ...
2026-04-09T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Kelun-Biotech Approved by HKEX to Remove "B" Marker from Stock Code, Representing a New Stage of Development
CHENGDU, China , April 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that following an application ...
2026-04-09T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
NSG Bio and Charles River Sign Memorandum of Understanding to Strengthen Support for Biotech Innovation in Singapore
Partnership to expand ecosystem connectivity, expertise access, and enablement for life sciences companies ...
2026-04-09T    Biotechnology   Computer/Electronics   Health Care/Hospital 
First Implant of KingstronBio's ProStyle M® Transcatheter Mitral Valve System Successfully Completed in National Multicenter Confirmatory Study
SHANGHAI , April 8, 2026 /PRNewswire/ -- On March 12, 2026, the first implant of the ProStyle M ® Transcatheter Mitral Valve System (ProStyle M ® ) was successfully completed under pure ...
2026-04-08T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical Equipment 
Portrai to Present 11 Posters on AI-Driven Spatial Transcriptomics at AACR 2026
The South Korean spatial biology company unveils new AI agents, foundation models, and spatial biomarkers for oncology drug discovery. ...
2026-04-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation
SHANGHAI , April 7, 2026 /PRNewswire/ -- ATLATL Innovation Center (hereinafter referred to as "ATLATL"), a global innovation platform for life science research and development, announced an ...
2026-04-08T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.